Adherium

Adherium Debt Growth

The Year-over-Year Debt Growth of Adherium (ADR.AX) as of Nov 2, 2026 is -23.03 %. In the previous year, Year-over-Year Debt Growth was 3,248.16 % — a change of -100.71% (lower).

Debt Growth

-23.03 %

YoY

-100.71%

Last updated:

Year-over-Year Debt Growth of Adherium is 2026 -23.03 % . Year-over-Year Debt Growth of Adherium was 2025 3,248.16 % . It decreases by -100.71% lower compared to the previous year.

The Adherium Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2017
-61.02 AUD
Jan 1, 2018
-68.65 AUD
Jan 1, 2019
-90.87 AUD
Jan 1, 2020
-100.00 AUD
Jan 1, 2023
-35.90 AUD
Jan 1, 2024
111.83 AUD
Jan 1, 2025
3,248.16 AUD
Jan 1, 2026
-23.03 AUD
The Adherium Debt Growth history
YEARDebt GrowthYoY
-23.03 %-100.71%
3,248.16 %+2,804.56%
111.83 %-411.54%
-35.90 %-64.10%
-100.00 %+10.05%
-90.87 %+32.36%
-68.65 %+12.51%
-61.02 %-145.96%
132.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adherium Stock analysis

What does Adherium do? Adherium Ltd develops and supplies connected medical devices and respiratory medications for patients, pharmaceutical companies, healthcare providers, and contract research organizations. The company generates revenue through its Hailie sensor technology and cloud-based data platform, which provides real-time feedback on patients' use of inhaled medication. The Hailie Remote Patient Management (RPM) Solution, Hailie Sensors, and Hailie Solution are key products sold to healthcare providers, payers, and pharmaceutical companies. These solutions enable optimal management of severe asthma and COPD, reduce healthcare costs, and offer remote monitoring capabilities for patients and physicians. The Hailie Sensor technology wraps around inhalers and connects via Bluetooth to capture medication use data, which is transmitted to the cloud-based Hailie platform. This platform delivers real-time feedback to patients through the Hailie app and to physicians via the Hailie portal. The company's focus on patient medication adherence and remote monitoring drives demand from healthcare providers seeking to improve treatment outcomes and from pharmaceutical companies aiming to enhance patient engagement with their respiratory medications. Adherium's products target segments including patients with severe asthma and COPD, healthcare providers managing chronic conditions, payers interested in cost reduction, and pharmaceutical companies developing respiratory medications. The company's revenue model centers on selling its sensor technology, cloud platform access, and integrated RPM solutions to these key segments, leveraging FDA-cleared devices to ensure compliance and reliability in healthcare settings. Adherium is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adherium stock

Year-over-Year Debt Growth of Adherium is -23.03 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Adherium since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Adherium historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Adherium

All Key Metrics — Adherium